JAK1 and neoplasm: Previous studies indicate that HDAC inhibition promotes LIFR transcriptional activation, which in turn activates the JAK1-STAT3 pathway and the antiapoptotic cascade, a mechanism contributing to tumor resistance to HDAC inhibition [53].